MXCT News & Events

The company said, "MaxCyte expects to end 2026 with at least $136 million in total cash, cash equivalents and investments."

Reports Q4 revenue $7.3M, consensus $9.16M. "Our 2025 revenues were impacted by headwinds from select SPL customers, including a 15% reduction in purchases and leases from our largest customer, which we expect to stabilize in the second half of 2026 and grow from that new base. Despite these near-term challenges, we made meaningful progress in 2025: reducing annual cash burn by more than $16 million, streamlining our cost structure, and advancing new product launches, all which we believe will strengthen MaxCyte's position in the growing cell and gene therapy market for the long term," said Maher Masoud, president and CEO of MaxCyte.

MaxCyte (MXCT) announced that it has appointed Parmeet Ahuja as CFO, effective March 30. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. Ahuja brings over 20 years of finance leadership experience across a global, publicly traded, life sciences organization, most recently serving as Vice President, Investor Relations at Agilent Technologies (A).